Arbios Systems, Inc's Q2/07 Analyst Review Issued by Scimitar Equity Research, Inc.
September 13 2007 - 9:00AM
PR Newswire (US)
BOSTON, Sept. 13 /PRNewswire/ -- Scimitar Equity Research, Inc.
(Scimitar) today issued a review on Arbios Systems, Inc. (OTC:ABOS)
(BULLETIN BOARD: ABOS) entitled: "Enhancing the Recovery of
Patients with Life Threatening Episodes of Liver Failure". The
analyst research review is available on Scimitar's website:
http://www.scimitarequity.com/ . About the SEPET(TM) Liver Assist
Device The SEPET(TM) Liver Assist Device is a sterile, disposable
cartridge containing microporous hollow fibers with proprietary
permeability characteristics. When a patient's blood is passed
through these fibers, blood plasma components of specific molecular
weights are expressed through the micropores, thereby cleansing the
blood of harmful impurities (i.e., hepatic failure toxins as well
as various mediators of inflammation and inhibitors of liver
regeneration). These substances would otherwise progressively
accumulate in the patient's bloodstream during liver failure,
causing hypotension, increasing risk of sepsis development and
accelerating damage to the liver, lungs and other organs, including
the brain and kidneys, and suppressing the function and
regeneration of the liver. SEPET(TM) is designed for use with
standard blood dialysis systems available in hospital intensive
care units. About Arbios Systems Arbios Systems, Inc. is developing
proprietary medical devices and cell- based therapies to enhance
the survival of millions of patients each year who experience, or
are at risk for, life-threatening episodes of liver failure. The
Arbios product candidate portfolio includes the SEPET(TM) Liver
Assist Device, a novel blood purification therapy that provides
enhanced "liver dialysis," and the HepatAssist(TM) Cell-Based Liver
Support System, a bioartificial liver that combines blood
detoxification with liver cell therapy to replace whole liver
function in patients with the most severe forms of liver failure.
For more information on ABOS.OB, please visit
http://www.arbios.com/ . Scimitar Equity Research, Inc. provides
sponsored equity research of the healthcare industry for the
institutional and investment communities. We certify that all the
views expressed in this review, accurately reflect our personal
views about ABOS.OB (NASDAQ:OTC:NASDAQ:BB) and its or their
securities. No part of our compensation was, is, or will be,
directly or indirectly, related to the specific recommendations or
views contained in this review and we will not have any investment
banking relationships or personal investment in any sponsored
company. Investors are advised that this analysis and review is
issued solely for informational purposes and is not to be construed
as an offer to sell or the solicitation of an offer to buy.
Scimitar was paid for preparing this review. This analysis and
review does not have regard to the specific investment objectives,
financial situation and the information contained herein is based
on sources that we believe to be reliable but is not guaranteed by
us as being accurate. Any opinions expressed are statements of our
own judgment as of the date of publication and are subject to
change without notice. Please read all our important disclosures.
CONTACT: Scimitar Equity Research, Inc. Henry W. McCusker Director
of Research phone: (617) 559-1080 fax: (617) 559-1083 e-mail:
DATASOURCE: Scimitar Equity Research, Inc. CONTACT: Henry W.
McCusker, Director of Research of Scimitar Equity Research, Inc.,
+1-617-559-1080, fax, +1-617-559-1083, Web site:
http://www.scimitarequity.com/ http://www.arbios.com/
Copyright